NL300391I2 - Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin - Google Patents

Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin

Info

Publication number
NL300391I2
NL300391I2 NL300391C NL300391C NL300391I2 NL 300391 I2 NL300391 I2 NL 300391I2 NL 300391 C NL300391 C NL 300391C NL 300391 C NL300391 C NL 300391C NL 300391 I2 NL300391 I2 NL 300391I2
Authority
NL
Netherlands
Prior art keywords
japanese encephalitis
weakened
vero cells
vaccine
virus adapted
Prior art date
Application number
NL300391C
Other languages
English (en)
Other versions
NL300391I1 (nl
Original Assignee
Cheil Jedang Corp
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cheil Jedang Corp, Us Army filed Critical Cheil Jedang Corp
Publication of NL300391I1 publication Critical patent/NL300391I1/nl
Publication of NL300391I2 publication Critical patent/NL300391I2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151Methods of production or purification of viral material
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NL300391C 1997-08-28 2009-06-10 Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin NL300391I2 (nl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR19970042002 1997-08-28
KR19970042001 1997-08-28
PCT/KR1998/000259 WO1999011762A1 (en) 1997-08-28 1998-08-25 An attenuated japanese encephalitis virus adapted to vero cell and a japanese encephalitis vaccine

Publications (2)

Publication Number Publication Date
NL300391I1 NL300391I1 (nl) 2009-08-03
NL300391I2 true NL300391I2 (nl) 2009-11-02

Family

ID=26633032

Family Applications (1)

Application Number Title Priority Date Filing Date
NL300391C NL300391I2 (nl) 1997-08-28 2009-06-10 Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin

Country Status (15)

Country Link
US (1) US6309650B1 (nl)
EP (2) EP1604685B1 (nl)
JP (1) JP4161017B2 (nl)
KR (1) KR100314404B1 (nl)
CN (1) CN1142271C (nl)
AU (1) AU748730B2 (nl)
CA (1) CA2301000C (nl)
DE (2) DE69837211T2 (nl)
DK (2) DK1025209T3 (nl)
ES (2) ES2382946T3 (nl)
FR (1) FR09C0037I2 (nl)
MY (1) MY129773A (nl)
NL (1) NL300391I2 (nl)
NZ (1) NZ503522A (nl)
WO (1) WO1999011762A1 (nl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000083657A (ja) * 1998-07-13 2000-03-28 Chemo Sero Therapeut Res Inst 日本脳炎ウイルスワクチン
AU743546B2 (en) * 1998-10-05 2002-01-31 Research Foundation For Microbial Diseases Of Osaka University, The Enhanced immunogen for inactivated vaccine for infection with Japanese encephalitis viruses and process for producing the same
JP4778620B2 (ja) * 1999-04-22 2011-09-21 ユナイテッド ステイツ デパートメント オブ アグリカルチャー 分離株ja−142に基づく、豚繁殖・呼吸障害症候群ワクチン
AU4472801A (en) * 2000-04-07 2001-10-23 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Inactivated japanese B encephalitis vaccine and process for producing the same
CA2451816A1 (en) * 2001-06-29 2003-01-09 Becton, Dickinson And Company Intradermal delivery of vaccines and gene therapeutic agents via microcannula
JP2007068401A (ja) * 2003-08-07 2007-03-22 Chemo Sero Therapeut Res Inst 西ナイルウイルスワクチン
EP1718738A2 (en) * 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
CN100340596C (zh) * 2004-05-20 2007-10-03 佛山市顺德区汉达精密电子科技有限公司 回收聚碳酸酯/丙烯腈-丁二烯-苯乙烯共聚物及其回收方法
CN101155915B (zh) * 2005-04-11 2013-12-04 克鲁塞尔荷兰公司 利用超滤进行病毒纯化
EP2117589A4 (en) * 2007-01-31 2010-07-21 Sanofi Pasteur Biologics Co FLAVIVIRUS VACCINE VECTOR AGAINST INFLUENZA VIRUS
AU2008342194B2 (en) * 2007-12-26 2014-03-20 Daiichi Sankyo Company, Limited Method of producing Japanese encephalitis vaccine stably storable over long time and use of the vaccine
WO2009147980A1 (ja) * 2008-06-04 2009-12-10 財団法人化学及血清療法研究所 不活化日本脳炎ウイルス粒子をアジュバントとして使用する方法
WO2010013601A1 (ja) * 2008-07-30 2010-02-04 久光製薬株式会社 マイクロニードルデバイスおよびマイクロニードルデバイスによる日本脳炎ウイルス抗原の奏功性を上昇させる方法
WO2010137036A2 (en) * 2009-05-25 2010-12-02 Panacea Biotec Ltd Novel japanese encephalitis vaccine and method of manufacturing the same
KR101144993B1 (ko) * 2009-06-18 2012-06-27 대한민국 돼지 일본뇌염 바이러스의 고농축 혈구응집용 항원
SI3106176T1 (en) 2011-12-06 2018-04-30 Valneva Austria Gmbh Aluminum compounds for use in therapeutics and vaccines
RU2706693C2 (ru) * 2013-09-14 2019-11-20 Бхарат Байотек Интернэшнл Лимитед Вирусная вакцина и способы ее производства
CN105695424B (zh) * 2015-04-01 2019-06-14 中国食品药品检定研究院 乙型脑炎减毒活疫苗株sa14-14-2在人二倍体细胞2bs上的适应株及其疫苗
EP3393507B1 (en) 2015-12-23 2024-02-07 Valneva Austria GmbH Zika virus purification
CA3010049C (en) 2016-01-15 2021-10-12 The Chemo-Sero-Therapeutic Research Institute Vaccine containing immobilized virus particles
WO2017210215A1 (en) 2016-05-31 2017-12-07 The Government Of The United States Of America As Represented By The Secretary Of The Army Zika virus vaccine and methods of production
NZ761619A (en) 2017-09-21 2024-03-22 Valneva Se Method of producing pharmaceutical compositions comprising immunogenic chikungunya virus chikv-delta5nsp3
SG11202003796XA (en) 2017-11-03 2020-05-28 Takeda Vaccines Inc Zika vaccines and immunogenic compositions, and methods of using the same
CA3085016A1 (en) 2017-11-30 2019-06-06 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
CN110684747B (zh) * 2018-07-06 2024-05-24 厦门大学 灭活及保存呼吸道合胞病毒的方法
US20210277361A1 (en) * 2018-08-27 2021-09-09 Mican Technologies Inc. Method for evaluating anti-infective drugs, vaccines, etc. using immortalized monocytic cells and induced cells
JP2023515908A (ja) 2020-03-01 2023-04-14 ヴァルネヴァ・オーストリア・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング CpGアジュバント化SARS-CoV-2ウイルスワクチン
EP3895729A1 (en) 2020-03-01 2021-10-20 Valneva Austria GmbH Cpg-adjuvanted sars-cov-2 virus vaccine
WO2021204825A2 (en) 2020-04-06 2021-10-14 Valneva Austria Gmbh INACTIVATED SARS-CoV-2 VIRUS VACCINE
WO2023148256A1 (en) 2022-02-02 2023-08-10 Valneva Austria Gmbh Inactivated sars-cov-2 virus vaccine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2704258B2 (ja) * 1987-10-31 1998-01-26 日本臓器製薬株式会社 組み換えワクチニアウイルス
GB8821656D0 (en) * 1988-09-15 1988-10-12 Health Lab Service Board Pharmaceutical compositions for eliciting immunostimulant effect
JPH085803B2 (ja) * 1988-11-10 1996-01-24 武田薬品工業株式会社 日本脳炎ワクチンの製造法
EP0562136A1 (en) * 1992-03-24 1993-09-29 Division Of Microbiology, Kyoto Biken Laboratories, Inc. Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
US6010894A (en) * 1997-06-13 2000-01-04 Research Development Foundation Method of screening for attenuating viruses

Also Published As

Publication number Publication date
NL300391I1 (nl) 2009-08-03
CN1142271C (zh) 2004-03-17
DE122009000037I1 (de) 2009-11-05
CA2301000A1 (en) 1999-03-11
ES2281929T3 (es) 2007-10-01
AU748730B2 (en) 2002-06-13
KR19990023955A (ko) 1999-03-25
ES2382946T3 (es) 2012-06-14
US6309650B1 (en) 2001-10-30
MY129773A (en) 2007-04-30
CN1272879A (zh) 2000-11-08
CA2301000C (en) 2003-07-08
EP1025209A1 (en) 2000-08-09
DE69837211D1 (de) 2007-04-12
JP4161017B2 (ja) 2008-10-08
KR100314404B1 (ko) 2002-10-12
DE69837211T2 (de) 2007-12-06
EP1604685B1 (en) 2012-02-22
WO1999011762A1 (en) 1999-03-11
FR09C0037I2 (fr) 2021-11-05
EP1604685A2 (en) 2005-12-14
EP1025209B1 (en) 2007-02-28
DK1604685T3 (da) 2012-06-18
DK1025209T3 (da) 2007-06-25
DE122009000037I2 (de) 2011-06-16
NZ503522A (en) 2001-06-29
FR09C0037I1 (nl) 2009-09-25
JP2001514844A (ja) 2001-09-18
EP1604685A3 (en) 2006-07-05
AU9004798A (en) 1999-03-22

Similar Documents

Publication Publication Date Title
NL300391I2 (nl) Een verzwakt Japanse encefalitus-virus aangepast aan Vero-cellen en een Japanse encefalitis vaccin
FI973457A (fi) Hepatiitti B -rokote
BR9609258A (pt) Vacinas contra hepatite c
NO981557L (no) Influensavaksine
NL300379I1 (nl) Bepaalde 5-alkyl-2- arylaminofenylazijnzuren en derivaten daarvan
NO20003303L (no) Vaksine
DE60018074D1 (de) Faltbarer einweg-dosieraerosolabstandshalter und verfahren dazu
ID22873A (id) Senyawa-senyawa heterosiklik dan pemakaiannya untuk menginhibisi b-amyloid peptida
HK1062827A1 (en) Cyclic amine derivatives and their use as drugs
IT1317988B1 (it) Procedimento e dispositivo per produrre depressione in un veicolo
EP1037974A4 (en) TRUNCATED PROTEIN OF HEPATITIS C VIRUS NS5B AND RELATED METHODS OF IDENTIFYING ANTIVIRAL COMPOUNDS
FI950567A (fi) Hepatitis A-virusrokote
HUP0104881A3 (en) Method to produce inactivated w/o emulsion adjuvated vaccines
DE69826593D1 (de) Neospora Impstoff
ATE262324T1 (de) Verkapslung einer untereinheit des bovinen herpes virus typ-1 in wässrigen lösungsmitteln als impfstoff.
GB9713979D0 (en) Method for attaching peg to macromolecules
ID26355A (id) Loop penggantung untuk sosis atau sejenisnya dan suatu metode untuk memproduksinya
HK1034202A1 (en) Combined vaccine against hepatitis a and hepatitisb
ATE240392T1 (de) Spezifische oligonukleotide fuer hepatitis c- virus
ID28381A (id) Vankoresmisin, suatu proses untuk memproduksinya dan penggunaanya sebagai obat-obatan
PT841943E (pt) Virus herpeticos avirulentos uteis como agentes tumoricidas e vacinas
HU9702540D0 (en) Carrying matherial for virus vaccine administered in intranasal way and virus vaccine itself
HU0400424D0 (en) Hepatitis virus vaccines
FR2789764B1 (fr) Analyseur d'impulsion de rayonnement unique et breve
KR970050438U (ko) 피엘엘과 디엘엘을 이용한 클럭발생 장치